Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 4 for:    BCG | Covid19 | Netherlands

Reducing Health Care Workers Absenteeism in Covid-19 Pandemic Through BCG Vaccine (BCG-CORONA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04328441
Recruitment Status : Active, not recruiting
First Posted : March 31, 2020
Last Update Posted : August 19, 2020
Sponsor:
Collaborator:
Radboud University
Information provided by (Responsible Party):
MJM Bonten, UMC Utrecht

Brief Summary:

Rationale: Covid-19 spreads rapidly throughout the world. A large epidemic in the Netherlands would seriously challenge the available hospital capacity, and this would be augmented by absenteeism of healthcare workers (HCW). Strategies to prevent absenteeism of HCW are, therefore, desperately needed to safeguard continuous patient care. Bacille Calmette-Guérin (BCG) is a vaccine against tuberculosis, with protective non-specific effects against other respiratory tract infections in in vitro and in vivo studies, and reported significant reductions in morbidity and mortality. The hypothesis is that BCG vaccination can reduce HCW absenteeism during the epidemic phase of Covid-19.

Objective: Primary objective: To reduce absenteeism among HCW with direct patient contacts during the epidemic phase of Covid-19. Secondary objective: To reduce hospital admission, ICU admission or death in HCW with direct patient contacts during the epidemic phase of Covid-19.

Study design: A placebo-controlled adaptive multi-centre randomized controlled trial.

Study population: HCW with direct patient contacts among which nurses and physicians working at emergency rooms and wards where Covid-19-infected patients are treated.

Intervention: Participants will be randomized between intracutaneous administration of BCG vaccine or placebo in a 1:1 ratio.

Main study parameters/endpoints: Primary endpoint: number of days of (unplanned) absenteeism for any reason. Secondary endpoints include the number of days of (unplanned) absenteeism because of documented Covid-19 infection, and the cumulative incidence of hospital admission, Intensive Care Admission, and death.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Based on previous experience and randomized controlled trials in adult and elderly individuals, the risks of BCG vaccination are considered low. The objective of this trial is to evaluate the beneficial effects of BCG vaccination through a lower work absenteeism rate of HCW and/or a mitigated clinical course of Covid-19 infection. The primary endpoint and the adaptive design with frequent interim analyses facilitate maximum efficiency of the trial, so that results can inform policy making during the ongoing epidemic.


Condition or disease Intervention/treatment Phase
COVID-19 Drug: BCG Vaccine Drug: Placebo Phase 3

Detailed Description:

Since the beginning of 2020, SARS-CoV-2 spread rapidly throughout China and the rest of the world, with on 27 February 2020 the first detected case in the Netherlands.

According to the WHO, Health-care workers (HCW) face an elevated risk of exposure to - and infection of Covid-19.

Bacillus Calmette-Guérin (BCG) was developed as a vaccine against tuberculosis, but studies have shown its ability to induce potent protection against other infectious diseases: the so called non-specific effects (NSEs). A favorable in vitro or in vivo effect has been observed in studies for distinct viral pathogens, e.g. respiratory syncytial virus, yellow fever, herpes simplex virus; human papilloma virus.

Based on the capacity of BCG to reduce the incidence of respiratory tract infections in children, to exert antiviral effects in experimental models; and to reduce viremia in an experimental human model of viral infection, the hypothesis is that BCG vaccination induces (partial) protection against susceptibility to and/or severity of Covid-19 infection. This study evaluates the efficacy of BCG to improve the clinical course of Covid-19 infection and to prevent absenteeism in order to safeguard continuous patient care.

This randomized controlled trial has been designed as a pragmatic study with a highly feasible primary endpoint, which is unplanned absenteeism, that can be continuously measured on a bi-weekly basis). This allows for the most rapid identification of a beneficial outcome that would allow other HCWs to also benefit from the intervention if and as soon as it has been demonstrated to be effective.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 1500 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: Unblinded are the pharmacist and the research nurse that administers the study medication. These persons are not involved in the further conduction of the trial or in the assessment of outcomes.
Primary Purpose: Prevention
Official Title: Reducing Health Care Workers Absenteeism in COVID-19 Pandemic by Enhanced Trained Immune Responses Through Bacillus Calmette-Guérin Vaccination, a Randomized Controlled Trial.
Actual Study Start Date : March 25, 2020
Estimated Primary Completion Date : March 31, 2021
Estimated Study Completion Date : April 30, 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: BCG vaccine
Intracutaneously 0.1ml BCG vaccine, which accounts for 0.075mg of attenuated Mycobacterium bovis.
Drug: BCG Vaccine
Intracutaneously 0.1ml BCG vaccine, which accounts for 0.075mg of attenuated Mycobacterium bovis
Other Name: Danish strain 1331

Placebo Comparator: Placebo
Intracutaneously 0.1ml of 0.9% NaCl solution
Drug: Placebo
Intracutaneously 0.1ml NaCl 0,9%
Other Name: NaCl 0,9%




Primary Outcome Measures :
  1. Health Care Workers absenteeism [ Time Frame: Maximum of 365 days ]
    Number of days of unplanned absenteeism for any reason


Secondary Outcome Measures :
  1. the cumulative incidence of documented COVID-19 [ Time Frame: Maximum of 365 days ]
  2. the cumulative incidence of Hospital Admission due to documented COVID-19 [ Time Frame: Maximum of 365 days ]
  3. the number of days of unplanned absenteeism, because of documented COVID-19 [ Time Frame: Maximum of 365 days ]
  4. the cumulative incidence of self-reported acute respiratory symptoms or fever [ Time Frame: Maximum of 365 days ]
  5. the cumulative incidence of death due to documented COVID-19 [ Time Frame: Maximum of 365 days ]
  6. the cumulative incidence of Intensive Care Admission due to documented COVID-19 [ Time Frame: Maximum of 365 days ]
  7. the number of days of absenteeism, because of imposed quarantine as a result of exposure to COVID-19 [ Time Frame: Maximum of 365 days ]
    Exploratory

  8. the number of days of absenteeism, because of imposed quarantine as a result of having acute respiratory symptoms, fever or documented COVID-19 [ Time Frame: Maximum of 365 days ]
    Exploratory

  9. the number of days of unplanned absenteeism because of self-reported acute respiratory symptoms [ Time Frame: Maximum of 365 days ]
    Exploratory

  10. the number of days of self-reported fever (≥38 gr C) [ Time Frame: Maximum of 365 days ]
    Exploratory

  11. the cumulative incidence of self-reported fever (≥38 gr C) [ Time Frame: Maximum of 365 days ]
    Exploratory

  12. the number of days of self-reported acute respiratory symptoms [ Time Frame: Maximum of 365 days ]
    Exploratory

  13. the cumulative incidence of self-reported acute respiratory symptoms [ Time Frame: Maximum of 365 days ]
    Exploratory

  14. the cumulative incidence of death for any reason [ Time Frame: Maximum of 365 days ]
    Exploratory

  15. the cumulative incidence of Intensive Care Admission for any reason [ Time Frame: Maximum of 365 days ]
    Exploratory

  16. the cumulative incidence of Hospital Admission for any reason [ Time Frame: Maximum of 365 days ]
    Exploratory

  17. the cumulative incidence and magnitude of plasma/serum antibodies (IgA,M,G) and SARS-CoV-2-specific antibodies at 12 weeks after vaccination and at the end of the study period [ Time Frame: Maximum of 365 days ]
    Exploratory

  18. the cumulative incidence and magnitude of plasma/serum antibodies (IgA,M,G) and SARS-CoV-2-specific antibodies at 12 weeks after vaccination and at the end of the study period [ Time Frame: 3-6 months after inclusion ]
    Exploratory



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Adult (≥18 years)
  • Male or female
  • Hospital personnel (expected to) taking care for patients with SARS CoV-2 infection

Exclusion Criteria:

  • Known allergy to (components of) the BCG vaccine or serious adverse events to prior BCG administration
  • Known active or latent Mycobacterium tuberculosis or with another mycobacterial species. A history with- or a suspicion of M. tuberculosis infection.
  • Fever (>38 C) within the past 24 hours
  • Pregnancy
  • Suspicion of active viral or bacterial infection
  • Vaccination in the past 4 weeks or expected vaccination during the study period, independent of the type of vaccination.
  • Severely immunocompromised subjects. This exclusion category comprises: a) subjects with known infection by the human immunodeficiency virus (HIV-1); b) neutropenic subjects with less than 500 neutrophils/mm3; c) subjects with solid organ transplantation; d) subjects with bone marrow transplantation; e) subjects under chemotherapy; f) subjects with primary immunodeficiency; g) severe lymphopenia with less than 400 lymphocytes/mm3; h) treatment with any anti-cytokine therapies. i) treatment with oral or intravenous steroids defined as daily doses of 10mg prednisone or equivalent for longer than 3 months, or probable use of oral or intravenous steroids in the following four weeks
  • Active solid or non-solid malignancy or lymphoma within the prior two years
  • Direct involvement in the design or the execution of the BCG-CORONA study
  • Expected absence from work of ≥4 of the following 12 weeks due to any reason (holidays, maternity leave, retirement, planned surgery etc)
  • Employed to the hospital < 22 hours per week
  • Not in possession of a smartphone

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04328441


Locations
Layout table for location information
Netherlands
Jeroen Bosch ziekenhuis
Den Bosch, Brabant, Netherlands
Canisius Wilhelmina Ziekenhuis
Nijmegen, Gelderland, Netherlands
Radboud UMC
Nijmegen, Gelderland, Netherlands
Sint Maartenskliniek
Nijmegen, Gelderland, Netherlands
Noordwest Ziekenhuisgroep locatie Alkmaar
Alkmaar, Noord Holland, Netherlands
Hagaziekenhuis
Den Haag, Zuid-Holland, Netherlands
Leiden University Medical Center
Leiden, Zuid-Holland, Netherlands
Erasmus Medical Center
Rotterdam, Zuid-Holland, Netherlands
University Medical Center Utrecht
Utrecht, Netherlands
Sponsors and Collaborators
UMC Utrecht
Radboud University
Investigators
Layout table for investigator information
Principal Investigator: Marc Bonten, MD, PhD UMC Utrecht
  Study Documents (Full-Text)

Documents provided by MJM Bonten, UMC Utrecht:
Statistical Analysis Plan  [PDF] May 2, 2020

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: MJM Bonten, Prof. M.J.M. Bonten, UMC Utrecht
ClinicalTrials.gov Identifier: NCT04328441    
Other Study ID Numbers: NL73249.041.20
First Posted: March 31, 2020    Key Record Dates
Last Update Posted: August 19, 2020
Last Verified: August 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: The results of this study will be disclosed unreservedly at the end of the study.
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Informed Consent Form (ICF)
Clinical Study Report (CSR)
Analytic Code
Time Frame:

The content of the study protocol is published. The statistical analysis plan is attached. The informed consent form (in Dutch) could be obtained by sending a mail to one of the contact persons.

The clinical study report and analytic code could be obtained by sending a mail to one of the contact persons after publication of the study in a peer-reviewed journal.


Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by MJM Bonten, UMC Utrecht:
Health care workers
Additional relevant MeSH terms:
Layout table for MeSH terms
BCG Vaccine
Adjuvants, Immunologic
Immunologic Factors
Physiological Effects of Drugs